HomeGrants › PAR-25-281

Open

Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)

Federal funding opportunity PAR-25-281 from National Institutes of Health (Department of Health and Human Services).

Apply on Grants.gov →Application closes January 7, 2028

Posted
November 22, 2024
Closes
January 7, 2028
Cost sharing
No
Instrument
Grant
Assistance listing
93.242, 93.313
Category
Health
Archives
February 12, 2028

Program funding history

Awards made under Assistance Listing 93.242 across FY2024–FY2026, from public federal spending records.

FY2024 obligated
$1.8B
FY2025 obligated
$1.8B
FY2026 (to date) obligated
$945.1M
Awards in window
7,145

Top recipients: Yale Univ, University of Pittsburgh - of the Commonwealth System of Higher Education, Icahn School of Medicine at Mount Sinai, University of California, Los Angeles, Washington University, the

Source: USAspending.gov · refreshed July 2026

Synopsis

The purpose of this Notice of Funding Opportunity (NOFO) is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.

Who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source.

View on Grants.gov   Full announcement

Agency contact: National Institutes of Health · grantsinfo@nih.gov · 301-402-2541

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.

The free edition carries one clearly labeled sponsor slot. No spam, ever. Privacy

Similar grants

Never miss a funding deadline again

Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.

Get funding alerts